Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The association of type and number of high-risk criteria with cancer specific mortality in prostate cancer patients treated with radiotherapy

F. Chierigo, RS. Flammia, G. Sorce, B. Hoeh, L. Hohenhorst, Z. Tian, F. Saad, M. Graefen, M. Gallucci, A. Briganti, F. Montorsi, FKH. Chun, SF. Shariat, G. Guano, G. Mantica, M. Borghesi, N. Suardi, C. Terrone, PI. Karakiewicz

. 2023 ; 83 (7) : 695-700. [pub] 20230315

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23011572

BACKGROUND: To assess the association between of type and number of D'Amico high-risk criteria (DHRCs) with rates of cancer-specific mortality (CSM) in prostate cancer (PCa) patients treated with external beam radiotherapy (RT). METHODS: In the Surveillance, Epidemiology, and End Results database (2004-2016), we identified 34,908 RT patients with at least one DHRCs, namely prostate-specific antigen (PSA) >20 ng/dL (hrPSA), biopsy Grade Group (hrGG) 4-5, clinical T stage (hrcT) ≥T2c. Multivariable Cox regression models (CRM), as well as competing risks regression (CRR) model, which further adjust for other cause mortality, tested the association between DHRCs and 5-year CSM. RESULTS: Of 34,908 patients, 14,777 (42%) exclusively harbored hrGG, 5641 (16%) hrPSA, 4390 (13%) had hrcT. Only 8238 (23.7%) harbored any combination of two DHRCs and 1862 (5.3%) had all three DHRCs. Five-year CSM rates ranged from 2.4% to 5.0% when any individual DHRC was present (hrcT, hrPSA, hrGG, in that order), versus 5.2% to 10.5% when two DHRCs were present (hrPSA+hrcT, hrcT+hrGG, hrPSA+hrGG, in that order) versus 14.4% when all three DHRCs were identified. In multivariable CRM hazard ratios relative to hrcT ranged from 1.07 to 1.76 for one DHRC, 2.20 to 3.83 for combinations of two DHRCs, and 5.11 for all three DHRCs. Multivariable CRR yielded to virtually the same results. CONCLUSIONS: Our study indicates a stimulus-response effect according to the type and number of DHRCs. This indicates potential for risk-stratification within HR PCa patients that could be applied in clinical decision making to increase or reduce treatment intensity.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011572
003      
CZ-PrNML
005      
20230801133141.0
007      
ta
008      
230718s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pros.24505 $2 doi
035    __
$a (PubMed)36919872
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Chierigo, Francesco $u IRCCS Ospedale Policlinico San Martino, Genova, Italy $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada $u Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy $1 https://orcid.org/0000000173570758
245    14
$a The association of type and number of high-risk criteria with cancer specific mortality in prostate cancer patients treated with radiotherapy / $c F. Chierigo, RS. Flammia, G. Sorce, B. Hoeh, L. Hohenhorst, Z. Tian, F. Saad, M. Graefen, M. Gallucci, A. Briganti, F. Montorsi, FKH. Chun, SF. Shariat, G. Guano, G. Mantica, M. Borghesi, N. Suardi, C. Terrone, PI. Karakiewicz
520    9_
$a BACKGROUND: To assess the association between of type and number of D'Amico high-risk criteria (DHRCs) with rates of cancer-specific mortality (CSM) in prostate cancer (PCa) patients treated with external beam radiotherapy (RT). METHODS: In the Surveillance, Epidemiology, and End Results database (2004-2016), we identified 34,908 RT patients with at least one DHRCs, namely prostate-specific antigen (PSA) >20 ng/dL (hrPSA), biopsy Grade Group (hrGG) 4-5, clinical T stage (hrcT) ≥T2c. Multivariable Cox regression models (CRM), as well as competing risks regression (CRR) model, which further adjust for other cause mortality, tested the association between DHRCs and 5-year CSM. RESULTS: Of 34,908 patients, 14,777 (42%) exclusively harbored hrGG, 5641 (16%) hrPSA, 4390 (13%) had hrcT. Only 8238 (23.7%) harbored any combination of two DHRCs and 1862 (5.3%) had all three DHRCs. Five-year CSM rates ranged from 2.4% to 5.0% when any individual DHRC was present (hrcT, hrPSA, hrGG, in that order), versus 5.2% to 10.5% when two DHRCs were present (hrPSA+hrcT, hrcT+hrGG, hrPSA+hrGG, in that order) versus 14.4% when all three DHRCs were identified. In multivariable CRM hazard ratios relative to hrcT ranged from 1.07 to 1.76 for one DHRC, 2.20 to 3.83 for combinations of two DHRCs, and 5.11 for all three DHRCs. Multivariable CRR yielded to virtually the same results. CONCLUSIONS: Our study indicates a stimulus-response effect according to the type and number of DHRCs. This indicates potential for risk-stratification within HR PCa patients that could be applied in clinical decision making to increase or reduce treatment intensity.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    12
$a prostatektomie $x metody $7 D011468
650    12
$a nádory prostaty $x patologie $7 D011471
650    _2
$a prostatický specifický antigen $7 D017430
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a biopsie $7 D001706
655    _2
$a časopisecké články $7 D016428
700    1_
$a Flammia, Rocco Simone $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada $u Department of Maternal-Child and Urological Sciences, Policlinico Umberto I Hospital, Sapienza Rome University, Rome, Italy $1 https://orcid.org/0000000231290544
700    1_
$a Sorce, Gabriele $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada $u Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy $1 https://orcid.org/0000000324362412
700    1_
$a Hoeh, Benedikt $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany $1 https://orcid.org/0000000242386584
700    1_
$a Hohenhorst, Lukas $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany $1 https://orcid.org/0000000173688617
700    1_
$a Tian, Zhe $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada
700    1_
$a Saad, Fred $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada
700    1_
$a Graefen, Marcus $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Gallucci, Michele $u Department of Maternal-Child and Urological Sciences, Policlinico Umberto I Hospital, Sapienza Rome University, Rome, Italy
700    1_
$a Briganti, Alberto $u Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Montorsi, Francesco $u Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Chun, Felix K H $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Departments of Urology, Weill Cornell Medical College, New York City, New York, USA $u Department of Urology, University of Texas Southwestern, Dallas, Texas, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
700    1_
$a Guano, Giovanni $u IRCCS Ospedale Policlinico San Martino, Genova, Italy $u Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy
700    1_
$a Mantica, Guglielmo $u IRCCS Ospedale Policlinico San Martino, Genova, Italy $u Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy
700    1_
$a Borghesi, Marco $u IRCCS Ospedale Policlinico San Martino, Genova, Italy $u Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy
700    1_
$a Suardi, Nazareno $u IRCCS Ospedale Policlinico San Martino, Genova, Italy $u Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy
700    1_
$a Terrone, Carlo $u IRCCS Ospedale Policlinico San Martino, Genova, Italy $u Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada
773    0_
$w MED00010484 $t The Prostate $x 1097-0045 $g Roč. 83, č. 7 (2023), s. 695-700
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36919872 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801133138 $b ABA008
999    __
$a ok $b bmc $g 1963789 $s 1197837
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 83 $c 7 $d 695-700 $e 20230315 $i 1097-0045 $m The Prostate $n Prostate $x MED00010484
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Archiving options